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Summary
Colorectal cancer is the most common type of gastrointestinal cancer. In this article treatment protocols for colon can-
cer are disscussed, including adjuvant and neoadjuvant therapy for resectable disease and chemotherapy for advanced or 
metastatic colorectal cancer. Surgery is the only curative modality for localized colorectal cancer (stage I-III). Adjuvant che-
motherapy is standard for patients with stage III disease. It’s use in stage II disease is controversial, with ongoing studies 
seeking to confirm which markers might identify patients who would benefit. Surgical resection potentially provides the 
only curative option for patients with limited metastatic disease in liver and/or lung (stage IV disease). Chemotherapy 
rather than surgery is the standard management for metastatic disease. Biologic agents have a role in the treatment of meta-
static disease, with selection increasingly guided by genetic analysis of the tumor.
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SISTEMSKO LIJE^ENJE RAKA DEBELOG CRIJEVA
Sa`etak
Rak debelog crijeva naj~e{}i je zlo}udni tumor probavnog sustava. U ovom se radu raspravlja o protokolima koji se 
primjenjuju u lije~enju raka debelog crijeva, uklju~uju}i adjuvantnu i neoadjuvantnu terapiju resektabilne bolesti te kemo-
terapiju uznapredovalog i metastatskog raka debelog crijeva. Kirurgija je jedini kurativni modalitet lije~enja lokaliziranog 
rakadebelog crijeva (stadij bolesti I-III). Adjuvantna kemoterapija predstavlja standard u lije~enju bolesnika sa stadij bolesti 
III . Me|utim, njezina uloga kod stadija bolesti II je kontroverzna te se trenutno provode studije koje tra`e biljege pomo}u 
kojih bi se mogli prepoznati bolesnici koji bi mogli imati koristi od primjene adjuvantne kemoterapije. Kirur{ka resekcija 
potencijalno predstavlja jedinu kurativnu mogu}nost za bolesnike s bole{}u ograni~enom na jetru i/ili plu}a (stadij IV). U 
lije~enju metastatske bolesti standard predstavlja kemoterapija, prije nego kirurgija. Biolo{ki lijekovi imaju ulogu u lije~enju 
metastatske bolesti, s tim da se njihov izbor sve vi{e temelji na genetskoj analizi tumora.
KLJU^NE RIJE^I: rak kolorektuma, sistemska terapija, adjuvantna terapija, neoadjuvantna terapija
Colon and rectal cancer (CRC) is an impor-
tant public health problem and it is responsible for 
million of new cancer cases and half a million of 
deaths worldwide per year1,2. In Europe, 250,000 
new patients are recorded yearly, of which 70% 
are older than 65 years2. In order to reduce mortal-
ity, optimal diagnostic methods for early diagno-
sis, appropriate surgical procedure (R0 resection) 
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and a strategy to select the most appropriate sys-
temic treatment to improve disease control and 
survival are required.
Patients with stage III (any T, N1, M0, or Any 
T, N2, M0) and high risk stage II (T3, N0, M0 or T4, 
N0, M0) colorectal cancer have benefit from adju-
vant therapy, which depends on the tumor differ-
entiation, , lymphatic, vascular and perineural in-
vasion, , clinical presentation with obstruction or 
perforation of the intestine and the number of re-
moved lymph nodes (12). In terms of the low-
risk,following factors may be important in the as-
sessment: p53, K-ras mutation, bcl-2 expression 
(apoptosis antagonist), transforming growth fac-
tor (TGF-alpha), epidermal growth factor (EGF) 
and the proliferative index of tumor cell. These 
prognostic parameters are not yet implemented in 
every day clinical praxis.
Fluoropyrimidines are basis for adjuvant 
treatment of colorectal cancer. Results of the 
NSABP C-01 study have shown the advantage of 
the addition of adjuvant chemotherapy compared 
to surgical resection alone (DFS 16%, OS 18%)1. 
An orally administered capecitabine is not inferior 
to fluoropyrimidine infusion protocol (X-ACT 
study) with the sameDFS2,3,4. The addition of ox-
aliplatin to fluoropyrimidine basis became the 
standard for stage III disease treatment based on 
the results of the MOSAIC study (risk reduction 
23% after three years and an absolute benefit in 
OS of 4.2% after six years in the group treated with 
FOLFOX)5,6,7. Similar results were confirmed in 
studies NSABP C-07 (FU/LV vs. FLOX) and 
NO16968 (XELOX)8. Adding irinotecan to 5-FU 
showed no advantage with the deterioration of 
the toxic profile (CALGB-89803 study, ACCORD 
and PETACC-3)2,9,10.
Although much was expected from the ap-
plication of biological therapy, it is not justified in 
the adjuvant treatment. Results of the AVANT 
study in which bevacizumab was added to FOLF-
OX4 protocol showed no significant clinical bene-
fit with more side effects11. Similar results were 
confirmed with FOLFOX6 protocol (NSABP C-
08)12. No clinical benefitswere shown when cetux-
imab was addedto FOLFOX4 protocol inK-RAS 
wild subtype patients in PETACC-8 study13. An-
swers to questions,such as why drugs which are 
effective in metastatic disease are not effective in 
adjuvant treatment and what factors affect their 
ineffectiveness in micrometastatic environment, 
may be clarified by studies currently in progress: 
QUASAR2, E5202, INT NO 147. Also,optimum 
time of application of adjuvant therapyremains 
unclear: six-months or three-months therapy. An-
swer to that question may be provided by the re-
sults of six ongoing clinical trials14.
Since 2004 neoadjuvant treatment of rectal 
cancer became a standard after results of two im-
portant clinical studies for T3, T4, or N + (positive 
regional lymph nodes) rectal cancer were an-
nounced. NSAPB R-03 study showed that preop-
erative chemoradiotherapy compared to postop-
erative insignificantly improves five-year progres-
sion-free survival (65% vs. 53%) and insigni-
ficantly improves five-year survival rate (75% vs. 
66%) with no effect on the incidence of local recur-
rence (11%). Pathological complete response was 
around 15%15,16,17,18. On the contrary CAO/ARO/
AIO-94 study, after eleven years of follow-up, 
showed a lower incidence of local recurrence (7.1% 
vs. 10%), a higher incidence of sphincter preserva-
tion (39% vs. 20%) and less acute and chronic tox-
icity in comparison with postoperative chemoradi
otherapy,without significant difference in five-
year survival (59%) and occurrence of distant me-
tastases15,19,20.
Usefulness of the adjuvant chemotherapy 
was confirmed by Sweden population study pub-
lished in 2013. Study included 2400 patients with 
stage III rectal cancer, of whom 79% had received 
preoperative radiotherapy (90% short-course, 25 
Gy in 5 fractions of 5 Gy), and after surgery 42% of 
patients continued adjuvant chemotherapy with 
5-FU/LV (DeGramont protocol) for 12 cycles. 
Study showed significant benefit of adjuvant che-
motherapy with five-year survival rate of 65.8% 
vs. 45.6% without chemotherapy, while reducing 
the risk of death by 35 %. Patients with tumors lo-
cated more than 10 cm above the anocutaneous 
line, patients between 50 and 60 years, and pa-
tients younger than 70 years have benefited the 
most from adjuvant chemotherapy21. Completely 
conflicting results were given by the EORTC 22921 
study published in 2014. That study included 1011 
patients with stage III rectal cancer who received 
preoperative radiotherapy (45 Gy in 25 fractions) 
with or without5-FU/LV chemotherapy, which 
was or was not continued with postoperative ad-
juvant therapy with 5-FU/LV for another 4 cycles. 
The results showed that adjuvant chemotherapy 
based on fluoropyrimidine after preoperative ra-
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diotherapy with or without concomitant chemo-
therapy does not affect recurrence-free survival 
and overall survival. This study, therefore, does 
not support the application of adjuvant chemo-
therapy after preoperative radiotherapy or radio-
chemotherapy. New researches, that will confirm 
or disprove this opinion, need to be conducted, 
and results are expected from five ongoing stud-
ies22,23. The questions how to accurately identify 
patients who are optimal candidates for preopera-
tive chemoradiotherapy, which chemotherapy 
drugwill be most effective and during which pe-
riod of time should that drug be used, remains. 
Controversy of ideal preoperative approach also 
remains due to the fact that niether short-course 
irradiation nor long-course chemoirradiation 
showed statistically significant difference in over-
all survival, incidence of distant metastases and 
local disease control, except definitive difference 
in the costs of treatment . Optimal moment for 
surgicalprocedure after chemoradiotherapy is still 
undefined27,28.
Patients with stage II are treated better thanks 
to early screening and improved surgical tech-
niques. The five-year survival rate is around 90%. 
Further progress can be achieved by analyzing 12 
genes (OncotypeDX), but without predictive sig-
nificance for the usefulness of adjuvant treat-
ment29,30,31. Similar results were obtained by Colo-
Print test which analyzes 18 prognostic genes32,33. 
Both tests have confirmed their independence in 
relation to the standard TNM classification.
The group of patients with potentially resect-
able metastases should be especially pointed out 
(liver, lungs). In that group of patients any active 
protocol could be applied. The order of adminis-
tration of chemotherapy is not clearly defined. 
There are several possible approaches (neoadju-
vant or perioperative therapy or liver resection 
first). Perioperative therapy should be based on 
protocols for metastatic disease for a total time of 
six months. Caution is needed when applying the 
protocol based on oxaliplatin and irinotecan due 
to the potential hepatotoxicity34,35,36. The addition 
of bevacizumab to irinotecan showed higher ef-
fectiveness than tooxaliplatin, but the overall re-
sults were modest37,38,39. Cetuximab in addition to 
standard FOLFIRI protocol showed the highest ef-
fectiveness in the overall response and the per-
centage of R0 resection, but showed no impact on 
overall survival, which was confirmed by a meta 
analysis40,41,42.Radiographic examination is requi-
red every two months during the course of treat-
ment, and planned surgical procedure should be 
performed as early as possible after achieving re-
sectability43.
Although by definition metastatic disease is 
incurable, in the last decade, we have witnessed 
great progress in the treatment of patients with 
metastatic colorectal cancer (mCRC). In addition 
to the therapy based on 5-fluorouracil as the sole 
active drug, now we have a whole range of new 
available drugs including irinotecan, oxaliplatin, 
capecitabine, and biological drugs such as bevaci-
zumab, panitumumab, regorafenib and ziv-af-
libercept. With the development of a multidisci-
plinary approach to treatment (surgery, radiofre-
quent ablation, CyberKnife, radioembolisation), 
certain percentage of patients with metastatic dis-
ease can be potentially cured.
Metastases will occurin about 50-60% of pa-
tients with CRC, mostly in the liver. Seventy per-
cent of these patients were initially unresectable, 
10% were resectable and 20% borderline resect-
able. 8% of partially resectable patients will be-
come resectable and potentially curable by using 
chemo +/– biological therapy44. In summary, only 
4% of patients will ultimately be treated with cu-
rative surgery, while others will be treated with 
some form of systemic therapy. Chemotherapy 
+/– biological therapy makes the basis of treat-
ment of unresectable patients with the primary 
goal of long-term survival and preservation of 
quality of life.
Today we no longer talk about certain lines 
of treatment, but the continuity of treatment. The 
choice of treatment depends on the characteristics 
of the patients and the available therapeutic op-
tions. For now there is no clear stand about which 
chemotherapy regimen should be used as first line 
treatment. Recommended protocols are FOLFIRI, 
FOLFOX, CapeOx, infusion FU/LV or capecitabi-
ne and FOLFOXIRI.
Studies have shown that the initiation of 
treatment with FOLFOX protocol is as effective as 
treatment with FOLFIRI protocol45. In the U.S., 
70% of patients starts treatment with FOLFOX 
whilein Croatia, as well asin the rest of Europe, 
most of patients usually start with FOLFIRI. Cer-
tain differences in the protocols can be found in 
the profile of side effects (peripheral sensory neu-
ropathy vs. alopecia and diarrhea).
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Problem of neuropathy can be mitigated by 
using the so-called “stop-and-go” approach. OP-
TIMOX1 study showed that the FOLFOX protocol 
can be administered in a way to have intervals 
without the use of oxaliplatin and that it will not 
affect the patients overall survival46. A practical 
recommendation is to limit the use of oxaliplatin 
to three months or less,in the purpose of prevent-
ing or reducing the side effects,and to continue 
with maintenance therapy up to 6 months or until 
disease progression. In the case of neuropathy, ox-
aliplatin therapy may be continued only after the 
withdrawal of symptoms to a level very close to 
complete absence of symptoms.
Infusion 5-fluorouracil+leucovorin or capeci-
tabine (–/+ bevacizumab) are therapies of choice 
in patients with poor general condition and pa-
tients who are not able to withstand the aggres-
sive forms of treatment47. We should point out the 
population of patients older than 70 years in which 
addition of bevacizumab ledto prolongation of 
PFS(9.1 vs. 5.1 months; AVEX study)48.
In order to get answers to questions, which 
protocol should we begin treatment with, should 
we add biological therapy, what type of biological 
therapy should we add, how to position the surgi-
cal procedure and maintenance therapy, great at-
tention is paid to potential biomarkers. Appropri-
ate biomarker could define groups of patients who 
will respond best to treatment, as well as those 
who will not benefit from the treatment at all and 
it would reduce the toxicity and treatment costs. 
Talking about the origin of biomarkers of tumor 
tissue, it remains unclear whether we should refer 
to the characteristics of the primary tumor or me-
tastasis when choosing the right therapy. Ger-
linger and colleagues published an interesting pa-
per in which they pointed out intratumour hetero-
geneity in the same person who underwent biopsy 
of multiple metastatic site49. This research has 
opened up a whole series of questions about the 
type and time of drug administration based on the 
status of biomarkers. Positive examples of defin-
ing biomarkers from the primary tumor site are 
the applications of cetuximab and panitumumab.
Use of the EGFR inhibitor is indicated in pa-
tients with wild-type KRASexon 2, whichwas 
clearly confirmed by meta-analysis of 14 random-
ized clinical trials50.In remaining 40% of patients 
there is a mutation of codon 12 and 13 of exon 2 so 
anti-EGFR therapy has no effect. Anti EGFR ther-
apy will, however, be useful in only 13 to 17% of 
patients with the wild-type KRAS exon 251,52.The 
PRIME study (FOLFOX +/– panitumumab as ini-
tial treatment) showed that in 17% of patients who 
don’t have mutation in KRAS exon 2 there is an 
additional KRAS mutation outside of exon 2 (exon 
3-4%; exon 4 -6%) and NRAS (exon 2 -3%; exon 
3 -4%)53. According to some literature dataNRAS 
mutation can be found in 2.6% of cases of colon 
cancer54. These findings require a change in cur-
rent terminology andnow we won’t be able to talk 
about KRAS but RAS mutation (which is already 
applied in the approval of panitumumab in Eu-
rope). There is a clear need to introduce the analy-
sis of RAS mutations in standard practice so we 
could isolate a small group of patients who will 
respond well to therapy. For now, there is no stan-
dardized test for determining RAS mutations but 
it can be determined in well-equipped laborato-
ries in Croatia. In patients with wild-type KRAS, 
who have progressed after or during chemothera-
py based on irinotecan/oxaliplatin, the use of pa-
nitumumab prolongs time to diseaseprogression 
comparing to best suppotive care51.BRAF muta-
tion that occurs in 4-14% of patients with CRC 
who do not show KRAS exon 2 mutations should 
also be mentioned. BRAF mutation is associated 
with poor prognosis, but it is not predictive of ef-
ficacy of panitumumab53. However, for now there 
is not enough data on the use of anti EGFR thera-
pies based on BRAF mutation.
CRYSTAL study, in which cetuximab was 
added to FOLFIRI protocol as initial treatment for 
mCRC, showed prolongation in overall survival55. 
OPUS and COIN studies have shown no benefit 
from the addition of cetuximab to FOLFOX/Cape-
OX protocol neither in the time to disease progres-
sion nor in the overall survival56,57.Results of direct 
comparison between addingcetuximab or bevaci-
zumab to FOLFIRI protocolin first line of treatment 
were expected with special interest. The answer 
was partly given by FIRE-3 study which showed-
prolongation of overall survival in KRAS wild-
type group who received cetuximab despite sur-
prisingly equal overall response and time to dis-
ease progression58,59. The results are a bit confusing, 
but very important to daily practice, although 
there are complaints about the lack of an indepen-
dent data processing and the small number of pa-
tients who received a second line therapy.
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Despite initial optimism, for now we are not 
able to confirm circulating VEGF-A as a biomarker 
of efficacy of bevacizumab. Anti VEGF therapy is 
standard treatment for patients with mCRC as an 
addition to FOLFIRI or FOLFOX protocol60,61,62. It 
has been proven that discontinuation of bevaci-
zumab does not cause “rebound” phenomenon63,64. 
Use of bevacizumab is indicated after progression 
on first-line of treatment regardless of previous 
application of bevacizumab. Studies TML and BE-
BYP justify continuation of bevacizumab therapy 
together with other chemotherapeutic partner af-
ter progression due toextension of overall surviv-
al, and the E3200 study justifies the application of 
bevacizumab in the second line of therapy when it 
was not used in the first line 65,66,67,68. VELOUR 
study has shown that the application of ziv-af-
libercept with FOLFIRI after progression on oxali-
platin provides a small (1.4 months) but statisti-
cally significant difference in overall survival69. 
Ziv-aflibercept is a recombinant fusion protein 
that functions according to the principle of the 
trap for VEGF and prevents angiogenesis. It 
should be applied only in combination with FOL-
FIRI protocol in patients who haven’t received it 
previously. Application ofziv-afliberceptis associ-
ated with therapy disruptions in 26% of patients 
due to adverse events (nausea , infections, diar-
rhea, high blood pressure).
Regorafenib is a tyrosine kinase inhibitor 
structurally very similar to sorafenib. The COR-
RECT study showed smallbut statistically signifi-
cant difference in overall survival compared to the 
best supportive care in patients previously treated 
with standard therapies70.
Although recent studies with regorafenib 
(CORRECT), ziv-aflibercept (VELOUR) and ex-
tended application of bevacizumab (TML) showed 
similar modest improvement in overall survival 
of 1.4 months, it still represents an additional step 
in extending the lives of patients with mCRC’s.
Patients should be additionally informed 
about the effectiveness of physical activity and 
healthy eating on treatment outcome (CALGB 
89803)71,72,73.
These findings suggest a smaller clinical sig-
nificance of classical TNM classification, the need 
for further genetic analysis, a personalized ap-
proach to the treatment and above all, better orga-
nized preventive actions.
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